Skip to main content
Fig. 3 | Cost Effectiveness and Resource Allocation

Fig. 3

From: Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

Fig. 3

PSA results for PHiD-CV 2+1 versus a no vaccination and b PCV13 2+1 vaccination programs. The “cost-effective” threshold was taken to be 3 × GDP per capita. GDP gross domestic product, PCV13 13-valent pneumococcal conjugate vaccine, PHiD-CV pneumococcal polysaccharide and NTHi protein D conjugate vaccine, PSA probabilistic sensitivity analysis, QALY quality-adjusted life-year, USD United States dollars

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us